In early March, in a rural Mississippi hospital, an infant was born to an HIV-infected mother. The chances of an infant contracting HIV from an infected mother not receiving antiretroviral treatment is around 25% in the U.S., and this child was on the wrong end of that statistic. Dr. Deborah Persaud, a Johns Hopkins Children’s Center HIV expert, knew that meant this baby would only have a 50% chance of living past the age of nine years.
Researchers have determined the structure of the rubella virus capsid protein, which is central...
A government study offers a new theory on why the whooping cough vaccine doesn't seem to be...
Viruses can not only cause illnesses in humans,...
Princeton Univ. officials decided Monday to make available a meningitis vaccine that hasn't been approved in the U.S. to stop the spread of the sometimes deadly disease on campus. The university said doses of the vaccine for the type B meningococcal bacteria are to be available in December for undergraduate students, graduate students who live in dorms and employees who have sickle cell disease.
A Univ. of Connecticut research team has found a way to stabilize hemoglobin, the oxygen carrier protein in the blood, a discovery that could lead to the development of stable vaccines and affordable artificial blood substitutes. The team’s approach involves wrapping the polymer poly(acrylic acid) around hemoglobin, protecting it from the intense heat used in sterilization and allowing it to maintain its biological function.
Princeton Univ. officials are deciding whether to give students a meningitis vaccine that hasn't been approved in the U.S. to stop the spread of the disease. A decision could be made as early as Monday. The Food and Drug Administration last week approved importing Bexsero for possible use on Princeton's campus.
Purdue Univ. researchers have successfully eliminated the native infection preferences of a Sindbis virus engineered to target and kill cancer cells, a milestone in the manipulation of this promising viral vector. The achievement also demonstrates the ability to use methods of manipulation previously only applied to proteins.
Merck said Monday that its new human papillomavirus vaccine was about 97% effective in blocking precancerous lesions caused by strains of the virus that are not stopped by Merck's vaccine Gardasil. Merck & Co. said it expects to file for marketing approval of the new vaccine, which is designated V503, before the end of 2013.
Doctors may one day be able to control a patient's HIV infection in a new way: injecting swarms of germ-fighting antibodies, two new studies suggest. In monkeys, that strategy sharply reduced blood levels of a cousin of HIV. The results also gave tantalizing hints that someday the tactic might help destroy the AIDS virus in its hiding places in the body, something current drugs cannot do.
A team of scientists has created an artificial protein coupled with a sugar molecule that mimics a key site on the outer coat of HIV where antibodies can bind to neutralize a wide variety of HIV strains. The finding provides a potential new strategy in vaccine development to elicit the broadly neutralizing antibodies considered essential for long-lasting protection from the ever-changing HIV virus.
Many viruses infect humans through mucosal surfaces. To help fight these viruses, scientists are working on vaccines that can establish a defense at mucosal surfaces. Vaccines can be delivered to the lungs via an aerosol spray, but are often cleared away before they can provoke an immune response. To overcome that, engineers have developed a new type of nanoparticle that protects the vaccine long enough to generate a strong immune response.
Researchers at The Scripps Research Institute discovered that an antibody that binds and neutralizes HIV likely also targets the body’s own “self” proteins. This finding could complicate the development of HIV vaccines designed to elicit this protective antibody, called 4E10, and others like it, as doing so might be dangerous or inefficient.
A cross-disciplinary team of scientists, engineers and clinicians announced that they have begun a Phase 1 clinical trial of an implantable vaccine to treat melanoma, the most lethal form of skin cancer. The effort is the fruit of a new model of translational research being pursued at Harvard Univ. that integrates the latest cancer research with bio-inspired technology development.
Scientists have developed an influenza vaccine delivered via microneedle patch that provided 100% protection against a lethal influenza virus in mice more than one year after vaccination. Instead of a liquid containing whole killed or attenuated virus, this vaccine uses dry virus-like particles which simply coat the needles in the presence of a simple stabilizing agent, reducing the need for refrigeration.
Scientists estimate that there is a minimum of 320,000 viruses in mammals awaiting discovery. Collecting evidence of these viruses, or even a majority of them, they say, could provide information critical to early detection and mitigation of disease outbreaks in humans. This undertaking would cost approximately $6.3 billion, or $1.4 billion if limited to 85% of total viral diversity.
Flu vaccination is no longer merely a choice between a jab in the arm or a squirt in the nose. This fall, some brands promise a little extra protection. For the first time, certain vaccines will guard against four strains of flu rather than the usual three. Called quadrivalent vaccines, these brands may prove more popular for children than their parents. That's because kids tend to catch the newly added strain more often.
When the HPV vaccine was first recommended for boys, health officials worried it would be an unusually hard sell. But a new report suggests that might not be the case. About one in five boys got at least one of the recommended three doses last year, relatively good for a new vaccine aimed at adolescents.
South Korea has approved $6 million in government aid for vaccines, medical care and food for North Korean children, officials said Tuesday, the first such humanitarian aid for Pyongyang since South Korean President Park Geun-hye took office in February.
Microbiologists in France are reinvigorating a way of battling C. difficile infections that they hope will help overcome the growing problem of antibiotic resistant superbugs in hospitals. Using a model human colon, the researchers showed that the administration of a specific bacteriophage significantly reduced toxins and the number of C. difficile cells produced without significantly affecting the other members of the gut microbiota.
Scientists in the U.S. have developed a novel vaccination method that uses tiny gold particles to mimic a virus and carry specific proteins to the body’s specialist immune cells. The technique differs from the traditional approach of using dead or inactive viruses as a vaccine and was demonstrated in the laboratory using a specific protein that sits on the surface of the respiratory syncytial virus.
People with serious egg allergies may no longer have to worry about flu shots. A federal advisory panel on Thursday said a new vaccine that's made without eggs is an option for adults with severe allergies. Current flu shots are made from viruses grown in eggs and could trigger allergic reactions in some cases.
Rice University students have created a way to help health care workers track vaccines and keep them at a safe temperature. The SAFE Vaccine senior engineering design team assembled a device to regulate the temperature of any standard refrigerator to keep it within a range that’s safe for vaccines. Their invention also tracks vaccine stock, usage, and expiration dates and, as a result, takes a load of paperwork off the backs of nurses.
A new global plan aims to end most cases of polio by late next year, and essentially eradicate the paralyzing disease by 2018 — if authorities can raise the $5.5 billion needed to do the work, health officials said Tuesday. Part of the challenge will be increasing security for vaccine workers who have come under attack in two of the hardest-hit countries. And the plan calls for changing how much of the world protects against polio, phasing out the long-used oral vaccine in favor of a pricier but safer shot version.
Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test. The results, released late Tuesday, show there's promise for similar vaccines other companies are developing.
Vaccines that employ weakened but live pathogens to trigger immune responses have inherent safety issues but Yale University researchers have developed a new trick to circumvent the problem—using bacteria’s own cellular mistakes to deliver a safe vaccine. The findings suggest new ways to create novel vaccines that effectively combat disease but can be tolerated by children, the elderly, and the immune-compromised who might be harmed by live vaccines.
Health officials are reporting an alarming increase in some dangerous superbugs at U.S. hospitals. These superbugs from a common germ family have become extremely resistant to treatment with antibiotics. Only 10 years ago, such resistance was hardly ever seen in this group. Infections from these superbugs are still uncommon. But in the first six months of last year, nearly 200 U.S. hospitals saw at least one case.
Better cancer drugs that zero in on a tumor with fewer side effects. A universal flu vaccine that could fight every strain of influenza without needing a yearly shot. Research into potentially life-saving products like these will be delayed and newer discoveries shelved if Congress can't avert impending budget cuts that the director of the National Institutes of Health warns will have far-reaching effects.
In the midst of an unusually deadly flu season and armed with a vaccine that only offers partial protection, a Purdue University researcher is working on a flu vaccine that overcomes the need to predict which strains will hit each year and eliminates the common causes of vaccine shortages.
- Page 1